Gokul Das
Associate Professor
Department of Pharmacology & Therapeutics
Roswell Park Cancer Institute
United States of America
Biography
Dr. Gokul Das works as an Associate Professor of Oncology in the Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. He also works as associate member for Molecular Pharmacology and Cancer Therapeutics Graduate Program, Experimental Therapeutics of CCSG (Comprehensive Cancer Support Grant) program, Breast, Lung, Genitourinary, and Gastrointestinal DSRGs (Disease Site Research Groups). His research interest includes: Interaction between estrogen receptors and tumor suppressor protein p53 signaling in breast cancer: understanding molecular mechanisms and identifying new prognostic markers and therapeutic targets, Role of p53 and estrogen receptor beta in non-small cell lung cancer (NSCLC) pathology, Cellular and molecular underpinnings of the role of estrogen receptors and mutant p53 in high grade serous ovarian cancer (HGSOC), Estrogen receptors and p53 in the regulation of nuclear-mitochondrial communication and energy metabolism, Clinical trials to translate research findings from the laboratory. He has received his PhD - Pharmacology & Molecular Biology from Baylor College of Medicine, Houston, Texas and has completed Postdoctoral studies from Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Research Interest
Interaction between estrogen receptors and tumor suppressor protein p53 signaling in breast cancer: understanding molecular mechanisms and identifying new prognostic markers and therapeutic targets, Role of p53 and estrogen receptor beta in non-small cell lung cancer (NSCLC) pathology, Cellular and molecular underpinnings of the role of estrogen receptors and mutant p53 in high grade serous ovarian cancer (HGSOC), Estrogen receptors and p53 in the regulation of nuclear-mitochondrial communication and energy metabolism, Clinical trials to translate research findings from the laboratory
Publications
-
Sayeed A, Konduri S, Liu W, Bansal S, Das GM, et al. (2007). Estrogen receptor inhibits p53-mediated transcriptional repression: Implications for the regulation of apoptosis. Cancer Research 67: 7746-7755
-
Konduri S, Medisetty R, Liu W, Kaipparettu B, Das GM, et al. (2010). Mechanisms of Estrogen receptor antagonism towards p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci, USA (PNAS) 107: 15081-15086
-
Putluri P, Maity M, Kommangani R, Creighton CJ, Das GM, et al. (2014). Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia 16: 330-402
